Hepatitis B virus receptors and molecular drug targets

被引:20
|
作者
Verrier, Eloi R. [1 ,2 ]
Colpitts, Che C. [1 ,2 ]
Sureau, Camille [3 ]
Baumert, Thomas F. [1 ,2 ,4 ]
机构
[1] Univ Strasbourg, INSERM, U1110, Inst Rech Malad Virales & Hepat, 3 Rue Koeberle, F-67000 Strasbourg, France
[2] Univ Strasbourg, F-67000 Strasbourg, France
[3] INTS, Lab Virol Mol, F-75015 Paris, France
[4] Inst Hosp Univ, Pole Hepatodigestif, Nouvel Hop Civil, F-67000 Strasbourg, France
基金
欧盟地平线“2020”; 加拿大健康研究院;
关键词
Antiviral targets; Host-targeting agents; Liver; Therapy; Treatment; HUMANIZED MICE; MONOCLONAL-ANTIBODIES; CYCLOSPORINE-A; IN-VIVO; ENTRY; INFECTION; HBV; HEPATOCYTES; INHIBITORS; BINDING;
D O I
10.1007/s12072-016-9718-5
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Chronic hepatitis B virus (HBV) infection is a leading cause of liver disease worldwide. Virus-induced diseases include cirrhosis, liver failure and hepatocellular carcinoma. Current therapeutic strategies may at best control infection without reaching cure. Complementary antiviral strategies aimed at viral cure are therefore urgently needed. HBV entry is the first step of the infection cycle, which leads to the formation of cccDNA and the establishment of chronic infection. Viral entry may thus represent an attractive target for antiviral therapy. This review summarizes the molecular virology and cell biology of HBV entry, including the discovery and development of new HBV entry inhibitors, and discusses their potential in future treatment of HBV infection.
引用
收藏
页码:567 / 573
页数:7
相关论文
共 50 条